Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsScientists evaluated outcomes in 581 patients who had undergone surgery and were evaluable for ctDNA from a randomized phase III trial of adjuvant atezolizumab versus observation in operable urothelial cancer.
[Nature]
6445218 {6445218:KZS726NK} apa 50 1 163493 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-1f85a9ce89f8d343543cc6f844a5df9f%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22KZS726NK%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Powles%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-16%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPowles%2C%20T.%2C%20Assaf%2C%20Z.%20J.%2C%20Davarpanah%2C%20N.%2C%20Banchereau%2C%20R.%2C%20Szabados%2C%20B.%20E.%2C%20Yuen%2C%20K.%20C.%2C%20Grivas%2C%20P.%2C%20Hussain%2C%20M.%2C%20Oudard%2C%20S.%2C%20Gschwend%2C%20J.%20E.%2C%20Albers%2C%20P.%2C%20Castellano%2C%20D.%2C%20Nishiyama%2C%20H.%2C%20Daneshmand%2C%20S.%2C%20Sharma%2C%20S.%2C%20Zimmermann%2C%20B.%20G.%2C%20Sethi%2C%20H.%2C%20Aleshin%2C%20A.%2C%20Perdicchio%2C%20M.%2C%20%26%23x2026%3B%20Mariathasan%2C%20S.%20%282021%29.%20ctDNA%20guiding%20adjuvant%20immunotherapy%20in%20urothelial%20carcinoma.%20%3Ci%3ENature%3C%5C%2Fi%3E%2C%201%26%23x2013%3B6.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41586-021-03642-9%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41586-021-03642-9%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DKZS726NK%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ctDNA%20guiding%20adjuvant%20immunotherapy%20in%20urothelial%20carcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Powles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zoe%20June%22%2C%22lastName%22%3A%22Assaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Davarpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Banchereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernadett%20E.%22%2C%22lastName%22%3A%22Szabados%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kobe%20C.%22%2C%22lastName%22%3A%22Yuen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petros%22%2C%22lastName%22%3A%22Grivas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Hussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephane%22%2C%22lastName%22%3A%22Oudard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00fcrgen%20E.%22%2C%22lastName%22%3A%22Gschwend%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Albers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Castellano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroyuki%22%2C%22lastName%22%3A%22Nishiyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Siamak%22%2C%22lastName%22%3A%22Daneshmand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shruti%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernhard%20G.%22%2C%22lastName%22%3A%22Zimmermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Himanshu%22%2C%22lastName%22%3A%22Sethi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexey%22%2C%22lastName%22%3A%22Aleshin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurizio%22%2C%22lastName%22%3A%22Perdicchio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jingbin%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20S.%22%2C%22lastName%22%3A%22Shames%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viraj%22%2C%22lastName%22%3A%22Degaonkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaodong%22%2C%22lastName%22%3A%22Shen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corey%22%2C%22lastName%22%3A%22Carter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Bais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joaquim%22%2C%22lastName%22%3A%22Bellmunt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjeev%22%2C%22lastName%22%3A%22Mariathasan%22%7D%5D%2C%22abstractNote%22%3A%22Minimally%20invasive%20approaches%20to%20detect%20residual%20disease%20after%20surgery%20are%20needed%20to%20identify%20patients%20with%20cancer%20who%20are%20at%20risk%20for%20metastatic%20relapse.%20Circulating%20tumour%20DNA%20%28ctDNA%29%20holds%20promise%20as%20a%20biomarker%20for%20molecular%20residual%20disease%20and%20relapse1.%20We%20evaluated%20outcomes%20in%20581%20patients%20who%20had%20undergone%20surgery%20and%20were%20evaluable%20for%20ctDNA%20from%20a%20randomized%20phase%20III%20trial%20of%20adjuvant%20atezolizumab%20versus%20observation%20in%20operable%20urothelial%20cancer.%20This%20trial%20did%20not%20reach%20its%20efficacy%20end%20point%20in%20the%20intention-to-treat%20population.%20Here%20we%20show%20that%20ctDNA%20testing%20at%20the%20start%20of%20therapy%20%28cycle%201%20day%201%29%20identified%20214%20%2837%25%29%20patients%20who%20were%20positive%20for%20ctDNA%20and%20who%20had%20poor%20prognosis%20%28observation%20arm%20hazard%20ratio%5Cu00a0%3D%5Cu00a06.3%20%2895%25%20confidence%20interval%3A%204.45%5Cu20138.92%29%3B%20P%5Cu00a0%3C%5Cu00a00.0001%29.%20Notably%2C%20patients%20who%20were%20positive%20for%20ctDNA%20had%20improved%20disease-free%20survival%20and%20overall%20survival%20in%20the%20atezolizumab%20arm%20versus%20the%20observation%20arm%20%28disease-free%20survival%20hazard%20ratio%5Cu00a0%3D%5Cu00a00.58%20%2895%25%20confidence%20interval%3A%200.43%5Cu20130.79%29%3B%20P%5Cu00a0%3D%5Cu00a00.0024%2C%20overall%20survival%20hazard%20ratio%5Cu00a0%3D%5Cu00a00.59%20%2895%25%20confidence%20interval%3A%200.41%5Cu20130.86%29%29.%20No%20difference%20in%20disease-free%20survival%20or%20overall%20survival%20between%20treatment%20arms%20was%20noted%20for%20patients%20who%20were%20negative%20for%20ctDNA.%20The%20rate%20of%20ctDNA%20clearance%20at%20week%5Cu00a06%20was%20higher%20in%20the%20atezolizumab%20arm%20%2818%25%29%20than%20in%20the%20observation%20arm%20%284%25%29%20%28P%5Cu00a0%3D%5Cu00a00.0204%29.%20Transcriptomic%20analysis%20of%20tumours%20from%20patients%20who%20were%20positive%20for%20ctDNA%20revealed%20higher%20expression%20levels%20of%20cell-cycle%20and%20keratin%20genes.%20For%20patients%20who%20were%20positive%20for%20ctDNA%20and%20who%20were%20treated%20with%20atezolizumab%2C%20non-relapse%20was%20associated%20with%20immune%20response%20signatures%20and%20basal%5Cu2013squamous%20gene%20features%2C%20whereas%20relapse%20was%20associated%20with%20angiogenesis%20and%20fibroblast%20TGF%5Cu03b2%20signatures.%20These%20data%20suggest%20that%20adjuvant%20atezolizumab%20may%20be%20associated%20with%20improved%20outcomes%20compared%20with%20observation%20in%20patients%20who%20are%20positive%20for%20ctDNA%20and%20who%20are%20at%20a%20high%20risk%20of%20relapse.%20These%20findings%2C%20if%20validated%20in%20other%20settings%2C%20would%20shift%20approaches%20to%20postoperative%20cancer%20care.%22%2C%22date%22%3A%222021-06-16%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41586-021-03642-9%22%2C%22ISSN%22%3A%221476-4687%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41586-021-03642-9%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-16T18%3A38%3A24Z%22%7D%7D%5D%7D
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., Albers, P., Castellano, D., Nishiyama, H., Daneshmand, S., Sharma, S., Zimmermann, B. G., Sethi, H., Aleshin, A., Perdicchio, M., … Mariathasan, S. (2021). ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature, 1–6. https://doi.org/10.1038/s41586-021-03642-9 Cite
